ACAD vs ASTI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Growth & Margin, Momentum & Technical while ASTI counters with relative strength in Valuation, Options & Structure. Fundamentally, ACAD trades at 15.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus ASTI at 14.4x Forward P/E and -2759.6% operating margin (+514.3% YoY). In options structure, ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against ASTI sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACAD Revenue | ASTI Revenue | ACAD Op. Margin | ASTI Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $220M | $0M | -110.6% | -761.8% | ACAD |
| FY2019 | $340M | $0M | -72.7% | -509.6% | ACAD |
| FY2020 | $440M | $0M | -64.9% | -3684.8% | ACAD |
| FY2021 | $480M | $0M | -35.2% | -1446.3% | ACAD |
| FY2022 | $520M | $0M | -43.2% | -1394.8% | ACAD |
| FY2023 | $730M | $0M | -10.1% | -3413.6% | ACAD |
| FY2024 | $960M | $0M | 24.1% | -20378.5% | ACAD |
| FY2025 | $1.07B | $0M | 9.8% | -10256.7% | ACAD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACAD | ASTI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $12.6M | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | 8.3x | 14.4x | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | 15.8x | 14.4x | Lower Multiple | ASTI |
| Revenue Growth (YoY) Growth | +22.8% | +514.3% | Higher Growth | ASTI |
| Operating Margin (TTM) Profitability | 10.2% | -2759.6% | Higher Margin | ACAD |
| Net Profit Margin Profitability | 30.1% | 0.0% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | 31.4% | -111.3% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 8% ($16โ$31) | 0% ($1โ$10) | Stronger Trend | ACAD |
| Beta / 30D Volatility Risk Regime | 0.15ฮฒ ยท 90% Vol | 4.37ฮฒ ยท 123% Vol | Lower Realized Risk | ACAD |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 44.5 / 100 (HOLD) | Higher Composite | ACAD |